CytoDyn is a publicly traded biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses. CytoDyn’s lead product candidate, PRO 140, has the potential to drive groundbreaking advancements in developing the next generation of HIV treatments.
Singular Research Summer Solstice 2018 Conference
July 19, 2018 at 2:50 pm ET
Convene Conference Center, New York, NY
Investment Community Conference Call
July 17, 2018 at 4:00 pm ET / 1:00 pm PT
Interested participants and investors may access this conference call by dialing 877-407-2986 (U.S./Canada) or 201-378-4916 (international).
A replay of the conference call will be available until September 17, 2018. To access the replay, interested parties may dial 877-660-6853 (U.S./Canada) or 201-612-7415 (international) and enter conference identification number 13672522.